Is The U.S. Biosimilar Industry Falling Behind?
Source: Life Science Leader
By ISR
Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more